2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160182
    INX-P 2734878-02-3 99.63%
    INX-P is glucocorticosteroid-target antibody drug conjugate (ADC).
    INX-P
  • HY-160224
    dsVACV-70mer sodium
    dsVACV-70mer (sodium) is a 70 bp double-stranded oligonucleotide containing viral DNA motifs derived from vaccinia virus DNA. dsVACV-70mer (sodium) has potently induces IFN-β via a STING-dependent manner.
    dsVACV-70mer sodium
  • HY-160550
    DPM-1003 3018836-86-4 98%
    DPM-1003 is a PTP1B conformational inhibitor that targets the non-catalytic, disordered segment at the C-terminus of the PTP1B protein, showing improvement in lung inflammation in mice.
    DPM-1003
  • HY-161115
    NR2E3 agonist 1 911211-69-3 99.48%
    NR2E3 agonist 1 (Compound 11a) is a small molecule agonist of the photoreceptor-specific nuclear receptor (NR2E3) with an EC50 value of less than 200 nM. NR2E3 agonist 1 can be used in retinitis pigmentosa research.
    NR2E3 agonist 1
  • HY-161158
    KCNK13-IN-1 361368-24-3 98.3%
    KCNK13-IN-1 (example 71), a KCNK13 antagonist, is an anti-inflammatory agent, with an IC50 of <200 nM for IL-1 β.
    KCNK13-IN-1
  • HY-161212
    HSD17B13-IN-8 2758802-02-5 99.97%
    HSD17B13-IN-8 (1) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with IC50 values of <0.1 μM for Estradiol and <1 μM for LTB3. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-8
  • HY-161227
    HSD17B13-IN-43 2770246-11-0 99.68%
    HSD17B13-IN-43 is a selective inhibitor of HSD17B13 that competitively blocks the activity of this enzyme. HSD17B13-IN-43 exhibits an IC50 ≤ 0.1 µM in in vitro assays. HSD17B13-IN-43 can be used in studies of non-alcoholic steatohepatitis, fatty liver disease and hepatic fibrosis.
    HSD17B13-IN-43
  • HY-161297
    NT-0249 2763617-39-4 98%
    NT-0249 is an orally active NLRP3 inhibitor. NT-0249 has anti-inflammatory activity
    NT-0249
  • HY-161477
    Histamine/BSA
    Histamine/BSA is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Histamine/BSA
  • HY-161526
    T3/KLH
    T3/KLH is an antigen-adjuvant conjugate formed by the coupling of T3 (thyroid hormone) with keyhole limpet hemocyanin (KLH). By coupling the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    T3/KLH
  • HY-161549
    Phosphotyrosine/BSA
    Phosphotyrosine/BSA is an antigen-adjuvant conjugate formed by coupling Phosphotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    Phosphotyrosine/BSA
  • HY-161552
    T3/BSA
    T3/BSA is an antigen-adjuvant conjugate of T3 (thyroid hormone) and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    T3/BSA
  • HY-161618
    MJ04 2099014-23-8 98.08%
    MJ04 is a selective inhibitor for Janus Kinase 3 (JAK 3) with an IC50 of 2.03 nM. MJ04 inhibits T cell differentation and inhibits the proinfammatory cytokines in Lipopolysaccharides (HY-D1056)‑induced macrophages. MJ04 exhibits good pharmacokinetic characters in mice, promotes hair growth in DHT-induced androgenetic alopecia (AGA) in athymic mice model, without significant toxicity (LD50 >2 g/kg).
    MJ04
  • HY-161901
    BC-1293 1219395-86-4 98.40%
    BC-1293 is an inhibitor for E3 ligase subunit FBXO24. BC-1293 disrupts the interaction between FBXO24 and aspartyl-tRNA synthetase (DARS2) and increases the level of DARS2. BC-1293 increases levels of IL-1β, IL-9, MIP-2, and TNF α, and exhibits immunostimulatory activity in mice.
    BC-1293
  • HY-162006
    Pim-1 kinase inhibitor 8 916038-47-6 99.90%
    Pim-1 kinase inhibitor 8 is a potent PIM-1 inhibitor with an IC50 value of 14.3 nM. Pim-1 kinase inhibitor 8 impedes cell proliferation and migration through PIM-1 inhibition and the induction of both apoptosis and autophagy. Pim-1 kinase inhibitor 8 inhibits solid tumor growth in Solid Ehrlich Carcinoma (SEC)-bearing mice. Pim-1 kinase inhibitor 8 can be used for breast and liver cancer research.
    Pim-1 kinase inhibitor 8
  • HY-162562
    E28362 930017-01-9
    E28362 is an orally active lipid-lowering agent and a selective PCSK9 antagonist. E28362 blocks the interaction between PCSK9 and LDLR, and induces PCSK9 degradation via the ubiquitin-proteasome pathway. E28362 significantly increases the levels of cell surface and total LDLR proteins, enhances low-density lipoprotein uptake, thereby effectively reducing plasma lipids, hepatic cholesterol and triglyceride levels. E28362 shows no obvious cytotoxicity at high concentrations, and significantly attenuates atherosclerotic lesions in animal models. E28362 is an important molecule in research of hyperlipidemia and atherosclerosis.
    E28362
  • HY-162588
    MC-ND-18 3081572-53-1 98%
    MC-ND-18 is an ATTEC degrader that degrades NLRP3 via the Autophagy pathway, with a DC50 of 125.5 nM in THP-1 cells. MC-ND-18 exhibits anti-inflammatory activity in a DSS-induced mouse model of colitis. MC-ND-18 can be used for research on inflammatory bowel disease. MC-ND-18 consists of an NLRP3 inhibitor (HY-156121), a linker (HY-W018745), and an LC3 ligand.
    MC-ND-18
  • HY-162632
    Hit 14 440338-68-1 ≥99.0%
    Hit 14 is an inhibitor for C-X-C chemokine receptor type 4 (CXCR4) with IC50 of 254 nM. Hit 14 inhibits the migration and invasion of cell MDA-MB-231. Hit 14 inhibits the Akt phosphorylation, exhibits anti-inflammatory activity, and ameliorateds the ear swelling and damage in mouse models.
    Hit 14
  • HY-162649
    TIC10g 754998-88-4 98.92%
    TIC10g is a dual inhibitor for toll-like receptor 7 and 9 (TLR7 and TLR9), which inhibits TLR7 and TLR9 mediated TNF-α release in mouse macrophages (IC50 is 14.5 μM and 6.5 μM) and human B lymphocytes (IC50 is 7.69 μM and 11.5 μM). TIC10g inhibits the activation of NF-κB and MAPK, and exhibits anti-inflammatory activity against systemic lupus erythematosus and rheumatoid arthritis .
    TIC10g
  • HY-162765
    TRPV4-IN-5 3046390-54-6 98.77%
    TRPV4-IN-5 (Compound 1f) is a potent TRPV4 inhibitor (IC50 = 0.46 μM). TRPV4-IN-5 significantly alleviates the symptoms of acute lung injury induced by lipopolysaccharide (HY-D1056) in mice.
    TRPV4-IN-5
Cat. No. Product Name / Synonyms Application Reactivity